Showing 6161-6170 of 6808 results for "".
- RXi Pharmaceuticals Receives FDA Orphan Drug Designation for Samcyprone for Melanomahttps://practicaldermatology.com/news/rxi-pharmaceuticals-receives-fda-orphan-drug-designation-for-samcyprone-for-melanoma/2458964/The FDA granted RXi Pharmaceuticals Corporation Orphan Drug Designation of its second clinical candidate, Samcyprone™, for the treatment of malignant melanoma Stage IIb to IV. A number of patients with Stage IIb to IV malignant melanoma develop cutaneous metastases. Samcyprone™ is bei
- Provectus Opens Phase 3 Trial Enrollment for Investigational Melanoma Agenthttps://practicaldermatology.com/news/provectus-opens-phase-3-trial-enrollment-for-investigational-melanoma-agent/2458965/Provectus Biopharmaceuticals, Inc. has opened enrollment of patients for its phase 3 international FDA comparative clinical trial of PV-10 for melanoma. The study is an international multicenter, open-label, randomized controlled trial of single-agent intralesional PV-10 versus systemic chemother
- Nerium International Announces Exclusive Usage of Anti-Aging Ingredient SIG-1273https://practicaldermatology.com/news/nerium-international-announces-exclusive-usage-of-anti-aging-ingredient-sig-1273/2458970/Nerium International added new ingredient, SIG-1273®, to the Optimera Formula of its Age-Defying Night and Day Creams. Engineered by Princeton University biochemist, Jeffry Stock, SIG-1273 is the result of 20 years of intensive biomedical skincare research, accordi
- Novan Secures $50 Million Private Financinghttps://practicaldermatology.com/news/novan-secures-50-million-private-financing/2458973/Novan Therapeutics, a clinical-stage biotechnology company focused on advancing innovation in dermatology via nitric oxide therapies, today announced that it has secured $50 million in an oversubscribed private financing. New investor Malin Corporation Plc. (MLC: ISE) functioned as the cornerston
- CareCredit Hosts Free Webinar on How to Host Successful Patient Eventshttps://practicaldermatology.com/news/carecredit-hosts-free-webinar-on-how-to-host-successful-patients-events/2458975/CareCredit will be sponsoring a free webinar to all aesthetic providers on how to host successful patient events. The webinar, How to Host Events That Bring Real Results: The Dos, Don’ts, and Definites, will be presented by Karen Zupko, President of Karen Zupko & Associate
- FixMySkin Unveils New Lookhttps://practicaldermatology.com/news/fixmyskin-unveils-new-look/2458974/FixMySkin Healing Balms with 1% Hydrocortisone have a new look with the same great formula. Now available in environmentally friendly packaging, these balms come in two convenient sizes for the lips and body. Th
- New Officers Assume Roles with the American Academy of Dermatologyhttps://practicaldermatology.com/news/new-officers-assume-roles-with-the-american-academy-of-dermatology/2458976/Mark Lebwohl, MD, FAAD, a dermatologist in New York City, took office as president of the American Academy of Dermatology (AAD). Timothy G. Berger, MD, FAAD, a dermatologist in San Francisco, also assumed his position as vice president of the AAD. Drs. Lebwohl and Berger assumed office at the con
- Signum Dermalogix Out-Licenses SIG990 to Dermata Therapeutics for Topical Treatment of Rosaceahttps://practicaldermatology.com/news/signum-dermalogix-out-licenses-sig990-to-dermata-therapeutics-for-topical-treatment-of-rosacea/2458979/Signum Dermalogix, Inc. entered into an agreement with Dermata Therapeutics to develop a topical product for the treatment of patients with rosacea. SIG990 is a novel, first-in-class anti-inflammatory compound, which has the potential to both reduce erythema and decrease the papules and pustules
- Promius Pharma Launches Zenatane 30mg Dosehttps://practicaldermatology.com/news/promius-pharma-launches-zenatane-30mg-dose/2458977/Promius Pharma, LLC has announced that ZENATANE™(Isotretinoin Capsules USP) are now available in a 30mg dose. Zenatane, AB rated equivalent to Accutane 30mg, has been introduced in response to dermatologists who have continued to request this strength of the drug. <
- Dermira Presents Clinical Data for DRM01 Acne Programhttps://practicaldermatology.com/news/dermira-presents-clinical-data-for-drm01-acne-program/2458981/Dermira, Inc. presented clinical data from its DRM01 Phase 2a trial in patients with facial acne vulgaris. The primary endpoints in this trial, the changes from baseline in inflammatory and non-inflammatory lesion counts and an improvement in the Investigator's Global Assessment (IGA) of acne